Anthropic Eyeing Over $900 Billion Valuation

25:21And so, you know, I think it is a problem. But, you know, it's something that we do everything we can to control. and try to help curtail. And it's affecting every one of the companies who are, you know, interesting in the private markets. Brian, you've been generous with your time. Before we lose you from the program, the president's visit to China, the timeline of the threat to Taiwan, 2027, what's Anderil's thinking on that? Look, diplomacy is good. We're in the deterrence business. We do not want there to be conflict. And I think the president going and engaging with Xi is a fantastic thing.

25:56And I'm very excited to see what comes out of this. And, you know, we're also providing a lot of technology to Taiwan, supporting them in every opportunity we can, because we believe that they need the right capabilities and to have the right deterrence. And the long-talked-about window of 2027, kind of the period of maximum danger, I think it is true. I don't think anyone believes that it was a January 1, 2027, an invasion begins. But it highlights a period where, you know, kind of the PRC has more established military capability and the U.S. and Taiwan at a relative disadvantage compared to other points in time.

26:41And so it is a period of significant risk. And with all of the complexities going on in the world with Iran, with Ukraine, with all the other areas that are hotspots in the world, it creates a significant stress on the U.S. military. So I think this is the opportunity for diplomacy is good to try to ensure that nothing does happen and try to find a scenario that preserves the status quo that is working reasonably well. And that's honestly what I hope for out of this summit. Brian Schimpf, fascinating. All things geopolitics, all things who are raised, $61 billion valuation, the Andrew Hill CEO.

27:17We so appreciate your time today. Look, it's expected to be the final day of evidence in the closely watched trial between Elon Musk and OpenAI. Yesterday, Sam Altman told jurors he was, quote, extremely uncomfortable with Musk's insistence on having full control of the startup in its early days. Musk, you'll remember, is suing OpenAI, his former co-founders, and Microsoft, alleging that they abandoned the ChatGPT maker's altruistic mission. Let's get more with Bloomberg's AI editor, Seth Figerman. So what seems to have transpired or what's being articulated by Sam Altman is that at some point, Elon Musk actually was thinking about a profit side of it, thinking about trying to earn control, and indeed was then thinking of bequeathing it to his children if he died, right?

28:01As one does. Yeah, a little bit of a dramatic testimony there. So much of OpenAI's counter-argument to Musk's claims here is that really his frustration is that he was not able to control and be CEO of OpenAI in the way that he is with all his other ventures. And so Sam Altman recounted a conversation with Musk where he allegedly said that, you know, if and when he were to die and he was in control of OpenAI, he would pass it along to his children. Now, you know, that's OpenAI saying it. But Altman also said that, you know, Musk wanted control in the early days but wasn't really willing to sign documentation saying that control would lift at some point.

28:37In his own testimony, Musk has said, yeah, he might have had control early on, but the expectation was more investors would come in, and eventually he wouldn't have that same level of control. Bloomberg, Seth Fingerman, we so appreciate the roundup. We have some breaking news, though, that we must hit, because crossing the terminal right now, Arm and its majority owner, SoftBank, reportedly tried to buy Cerebrus in an evenly split cash and stock deal that would have valued the upstart at$100 billion, according to sources. This all happened weeks before the chipmaker was due to make its public debut, of course.

29:10The person who's been busy breaking that story and also come anchoring this show on air is one Ed Ludlow. Talk us through it as to this was happening in the background during May. Yeah, look, Cerebris is going to list tomorrow, right? And this happened at the beginning of May. They very clearly said, no, we're not interested. But Arm and SoftBank, which Majority Owns Arm, tried. Why? Very interesting. We can get into it in the back half of the show because there's a lot more to come on Bloomberg Tech.

29:42Welcome back to Bloomberg Tech. Let's get back to that news that broke just a few moments ago. Arm and its majority owner SoftBank tried to buy Cerebrus. That's according to sources. My understanding is this all happened in the last couple of weeks, early May, and it's just before Cerebrus, the chip maker, is due to go public. Thursday, they were rebuffed. You know, Cerebrus said no. My understanding is Armistice Bank would have happily paid a premium, big premium. But Cerebrus backs itself and its leadership backs them. And the investors back them to do this alone as a public company. I mean, look at the demand for its IPO.

30:21It's going to be pricing today. We understand it's going to price at the top end of the marketed range up to$160 plus. us. We're seeing maybe the biggest amount raised in a semiconductor name since Arm went public, maybe even more if the green shoe allotment is used. But why would Arm and Cerebris have been sort of a useful synergy here? Well, because Arm goes from being a chip designer to wanting to be a chip maker, like actually sell directly into the market. And Cerebris in this phase of inference in AI, the broader infrastructure play, it backs itself as well. Anyway, I should just probably note that all of the parties involved declined to comment or did not immediately respond to comment to Bloomberg.

30:59We should check in on markets because markets are being driven by what's happening in Beijing. The Nasdaq 100, modestly higher, four-tenths of a percent. U.S.-listed Chinese companies, that's the Golden Dragon China index, up 4%. A big part of this is NVIDIA. Shares of Chinese AI model developers in particular surged after NVIDIA CEO Jensen Wang was announced to be joining President Trump's China trip. Shares of Minimax and GPO on the hopes of progress on NVIDIA's ability to sell chips into China. Look at those gains overnight. Bloomberg's Chinese equities reporter Henry Ren is with us. Henry, look at those gains overnight.

31:36I mean, the response in Asia trading was interesting. Yeah, that's right. So the last minute trip by Jensen Huang is boosting the morale of mainland traders. We're seeing double-digit gains in the likes of Zhipu and Minimax as well, the Chinese model makers, but not limited to that. That has obviously spread to today's U.S. trading session as well. We see Alibaba, JD, the likes of those Chinese tech names also trading higher in mainland session. We have the ChinaX index, which is China's equivalent of Nasdaq for those young tech companies also soaring to a record. So there are some optimism that China and U.S.

32:14could strike some form of deals on chip exports. And remember that NVIDIA has gained approval from Washington to sell H200 chips into China since end of last year. But still, there are some hopes that for more powerful models can be used. Really interesting that you bring up Alibaba, because actually Alibaba, Tencent, they gave us fundamentals as well. They came out with their earnings and thus far they're investing a ton. But the return on that investment from AI investment just doesn't seem to be there yet. Yeah, that's the huge issue that the market is focusing on today with both company reporting results.

32:53So probably we can start from Alibaba. So the company, I think it does reassure investors because it said its cloud revenue grew by about 40 percent in the first quarter. And that's the key number that market has been focusing on. That's an acceleration from the quarter earlier. So it does show that there are some AI trajectory going on. And in the meantime, it's also saying that for its AI related revenue related to its models, as well as application services, that will reach about 10 billion RMB for the June quarter. So that's a helpful additional disclosure as well. So it does show some AI momentum, but at the same time, that CapEx has been soaring, as you mentioned.

33:38Yeah, meanwhile, Tencent reported the slowest pace of revenue growth in over a year. Henry Ren, it's always great to catch up with you and the latest on all things China and AI. But now let's take a look at today's big number. It's around AI and it's over$900 billion. This is Anthropik's targeted new valuation, according to sources who say the company is in early talks with investors, to raise at least$30 billion in fresh financing. It could set the stage for what may be the largest funding round yet for the company. Though the deal has not been finalized, no term sheet has been signed. Natasha Masquerianas, who joins us now, who helped break this story alongside Ed.

34:13And just tell us a little bit about the inbound, almost the love letters they've been receiving from potential investors. It's a great way to describe it, Caroline. I mean, a few weeks ago, these were conversations that were coming completely unsolicited from Anthropics backers. Now we have reporting that they are engaging in those conversations and discussing a round that could see them raise at least 30 billion. And sources are telling us that the round could close as soon as the end of this month. It's one that we're tracking very closely and definitely the biggest update we've had on the round throughout this circus of interest.

34:48you know the private markets are alive you know to put it mildly and it's interesting this hasha you know anthropic feels comfortable now with this valuation here we've gone from a place in just the last two or three weeks where they rebuffed office and now you know we don't want to do this but the main thing that's happened in the interim is that claude continues to have momentum enterprise adoption of anthropic and then there's the me folks government angle um give us the sort of awkward elephant in the room, which is that if they close this round, they will have a valuation higher than OpenAI.

35:22Absolutely. I mean, this is a massive narrative shift around Anthropic, and we've been covering it relentlessly. Our understanding is that the investor interest far exceeds how much Anthropic will actually end up accepting from investors. And so you are seeing them maybe be picky on valuation, lead investor. The term sheet is not officially signed as of our reporting last evening, but we do expect that to change, you know, as fast as we're able to confirm it. And so the real question and what we're looking at next is, let's say Anthropic closes this round as per our sources as soon as the end of this month.

35:57Does this change their IPO timeline? Does it need to change their IPO timeline? I mean, you guys just had Brian Shimp from Anderil on the show who was saying that Anderil is raising just a quarter of what AI financing is. I'm curious what you think, Ed, about if this does change when we see the S1 officially filed for an anthropic. Well, it depends what happens with SpaceX June, July. Does that suck oxygen out of the room? But again, if the private markets provide, what's the need to go public? Bloomberg's Natasha Mascherinus teaming up on another big twist and turn in the anthropic story. Some breaking news regarding Misra, the AI giant of France, is apparently developing a new AI model for banks who lack access to Mythos.

36:40This is all about cybersecurity vulnerabilities. Already, Mistral of France had been working with local European banks to have a new model that would stress test cyber risks around the banks and more broadly in their systems. Well, now we understand those banks, of course, have been wanting access to Mythos. And now Mistral is looking to develop this new model that can uncover cybersecurity vulnerabilities at unprecedented speed and scale. Ed. That reporting all according to Bloomberg sources. Okay, VADA Space is planning to send medicines from United Therapeutics into orbit to explore the use of microgravity in creating drugs.

37:16It's one of the first commercial research deals to develop medicine molecules in space and then return them to Earth, though the mission is still in its early stages. I speak with VADA CEO Will Brewery. Let's talk timeline. This is an exciting development for you guys because it's a real commercial opportunity. When does it happen? What are the steps to start working with United? Yeah, thanks for having me, Ed. It's happening now, which is really exciting. The research has been done for decades. And so now we're moving into the commercial phase. VAR has been flying for years. And so this commercial endeavor will be putting drugs into space in the next year.

37:47We're working on those drugs right now in the lab with United. And when they're in space, what are you hoping to prove? What are you hoping to see? Where does this drive United? So the most confusing thing about VARTA is the space part. If you just imagine we had an anti-gravity technology. It's good to admit it. If you imagine we had an anti-gravity technology where we could manipulate chemical systems on Earth to improve formulations in a way that would otherwise be impossible, and by formulation I mean going from like an IV bag to a shot or better bioavailability, then it would make total sense.

38:16Now as shipping to space is becoming just shipping, we can access microgravity in a way that helps patients today. I've had the opportunity to sort of interact with, I don't know, you call it a spacecraft or if you call it a mini factory. But just go through the basics of who's the launch provider, what happens when you get into low Earth orbit, and then how long typically is the spacecraft or capsule in orbit? Sure. So I'll even step back just because we're so excited about this United announcement today. First, we work with the customers before we even get there. And we develop a microgravity enabled formulation on the ground in our lab in cooperation and partnership with United.

38:51Once those microgravity-enabled formulations are ready for flight... What does that look like, microgravity-enabled formulations? It means that the temperature profile, the concentration, all the parameters that would go into any other drug formulation now has the option of turning off gravity during the process, which means we can make a new outcome for patients. So then what we do is once we have that formulation, we load it into our spacecraft. Our launch provider is SpaceX. We put our spacecraft onto a Falcon 9 rocket. Dedicated or rideshare? Rideshare, which is great, because now we get to take advantage of good costs and frequent availability to space.

39:23So now the spacecraft separates from the rocket like it would any other satellite. So it looks like a satellite to SpaceX. You can fit 20 of these things on a single rocket. It's now orbiting the Earth. We do the manufacturing process where there isn't gravity affecting the sedimentation of the crystals. And then once those properties are locked in, our spacecraft flies itself back to Earth, lands in Australia, and now we have the drug for patients. And what does it help patients with? I mean, how is this going to unleash a whole new area of medicine? It's wild because gravity is a fundamental force of physics.

39:53So it's extremely broad technology, anything from bioavailability to shelf stability. A classic example that was flown on the International Space Station was going from an IV bag to a shot. So imagine you're in rural America and you don't have access to a clinic. You now have access to the drug because that same drug can be form factored into a shot instead of an IV bag. And that shot can come to you instead of you having to go to the clinic. We're showing images, right? This is images of VARDA returning to Earth. So this sounds ridiculous, and I'll say it anyway. You try and land in Australia.

40:25That seems quite easy. Australia's quite big. Actually, it's not. How restrictive is that landing pad of one continental nation? Yes, yes. So more than try. I mean, we've done this now four or five times. And the reason I say four or five, one of them was in Utah, and the rest were in Australia. How did that go in Utah? Oh, it was great. That was our first mission success. I see. Yeah. The thing that's nice about Australia is it's a commercial range, so we don't need to get in the way of the military operations that are happening at our test ranges so we can not disturb them while landing commercially.

40:57But it's great. I mean, it makes the process way easier. You're excited about United Therapeutics deal. Where next? What does this prove out for others? Well, this is just the tip of the tip of the iceberg because it's such a broad technology that affects so many drugs. You know, United is kind of in the future, and they have been for quite some time. And so we're really lucky to work with such a crack team. But this technology is broad, so it applies to a wide variety of pharmaceuticals for a wide variety of patients. Well, as that starts to go up into space, come back, join us, Wilbur A, CEO of Vata Space, on that new announcement.

41:36Meanwhile, there's been plenty of announcements coming out about agentic commerce and international expansion from a firm. It's just been reporting yesterday at the company's 2026 Investor Forum. The fintech company is laying out a bold roadmap to$100 billion in annual volume. Look, CEO Max Levchin, I'm pleased to say, joins us in New York, and I'm sad I'm not there next to you, Max. But tell us about what your I know. I know, too far. But I'm interested in what you told the investors, the analyst community in New York yesterday and for the next few days. How do you get to that sort of volume?

42:08Where are the growth factors? You know, the exciting thing is that literally everything we have been working towards is coming together and working incredibly well. We held a similar event three years ago and promised investors we'll get to$50 billion of gross merchandise volume, our merchant sales that we power. And we will do so by maintaining, while maintaining our profit margins between 3 % and 4%. We'll grow at 20 % per year or so. That was the story we told them three years ago. We've now come back. We're now basically at that$50 billion mark. You would expect us to slow down. But instead, we told our investor base yesterday, we expect to grow 25 % compounding, so five points extra.

42:48And we intend to up the floor of our profitability from three to 3.75%. So not only are we growing faster, not only are we reaching more consumers, more merchants, we intend to do this more profitably. And we feel it's just getting better and better for us. So that's the headline. And I had a lot of conversations yesterday that seemed to indicate that our investors are quite enjoying the news. Max, just very simply, why is a$100 billion volume target the right target, the right metric? When people try and understand a firm, like you come on the show often and we talk about the different offerings and some of the newer products that you're doing.

43:25This kind of North Star or achievable goal probably to your mind, it's really interesting that you've set that as it. You know, it is just a waypoint. We have absolutely no intention of slowing down or stopping at 100. It's just another nice round number that we can set our sights to. But we do see an incredible market pull. Consumers are ready. They are coming to us. We are now seeing inbounds from consumers that didn't discover us at the point of sale, which is the usual way, just signing up for a firm, asking us to send them a card so they can transact everywhere. That's been a huge pull. That's contributed to our growth tremendously.

43:58Merchants come to us saying, I've seen your logo on my competitor's sites. I know you're driving 10, 20 % more sales for them. You should do the same for us. Let us sign up. You should promote our sales events. Tell us, merchants, in your app because we're now reaching 15 million monthly consumers and so on. So just the tremendous amount of we're finally a real scalable thing that every constituent cares about a lot is what gives us the confidence to go towards this new milestone. Analysts liked it, like RBC talking about the pending industrial bank charter. That could be another strength area.

44:30the fact that you've got competitive advantage, but take us to the future and the agentic commerce future, because we talk about it a lot on the show, and you are already doing deals with Google. What does that look like in terms of how I'm going to be having a relationship with a firm going forward? I think it's going to be incredible. I cannot be more excited about this new AI-powered future in many different facets. As an engineer, as a coder, I love what we have today. As a consumer, as a buyer of complicated things, I love the help that AI provides me when I research the finer points of whatever it is that I'm after now.

45:05A firm is a great tool of buying things that are meaningful. When it matters, that's when consumers come to us. They want anything from a bicycle to a couch to an espresso machine. During those moments, you want to know that the financing choice you're making has your back, that you're not going to get hit with some unexpected fees. You know exactly when you're going to start and stop with your payments. That's what we've built. And agents just make it that much easier to bring to the end consumer. And the brand we've built allows people to trust us. The fact that we're able to partner with LLM providers allows us to be right there when consumers are searching and doing their research.

45:39So it's just an incredible incremental growth engine that we found. Max, you're again emphasizing the word built. You do that often. But how does quickly Max Lefcin think about M &A in a firm's future? You know, we've looked for years. We haven't found anything in the last few. So never say never, but we have so much to do just with the team that we have. It's, you know, when opportunities come up, we'll, of course, look at them. But we're very focused on building. Affirm CEO, Max Levchin, back on Bloomberg Tech. Thank you very much for your time today. Now, coming up, we're going to get back to what to expect from President Trump's meeting with Xi Jinping.

46:16And will AI be in focus? Probably. This is Bloomberg Tech. Support for the show comes from Public. Public is an investing platform that offers access to stocks, options, bonds, and crypto. And they've also integrated AI with tools that can assist investors in building customized portfolios. One of these tools is called Generated Assets. It allows you to turn your ideas into investable indexes. So let's say you're interested in something specific like biotech companies with high R &D spend, small cap stocks with improving operating margins, or the S &P 500 minus high debt companies. chances are there isn't an ETF that fits your exact criteria.

46:55But on public, you just type in a prompt and their AI screens thousands of stocks and build a one-of-a-kind index. You can even backtest it against the S &P 500. Then you can invest in a few clicks. Go to public.com slash market and earn an uncapped 1 % bonus when you transfer your portfolio. That's public.com slash market. Add paid for by Public Holdings. Brokered services by Public Investing, member FINRA SIPC. Advisory services by Public Advisors, SEC Registered Advisor, crypto services by ZeroHash. Sample prompts are for illustrative purposes only, not investment advice. All investing involves risk of loss.

47:30See complete disclosures at public.com slash disclosures. Small businesses are the pulse of every community. They bring people together, create opportunities, and drive growth. With a widespread presence in communities across the country, Chase for Business supports small business owners at a local level. That makes it possible for you to connect, learn from each other, and grow together. There's a real commitment to seeing small businesses succeed. The Chase for Business team has knowledge and expertise that span a wide range of financial areas. They can help you make more informed decisions as you navigate the complexities of running your business.

48:05They'll help your business grow with individual guidance and convenient digital tools all in one place. With that guidance and your determination, you can take your business farther and help build a brighter future for your community. Learn more at chase.com slash business. Chase for business. Make more of what's yours. The Chase mobile app is available for select mobile devices. Message and data rates may apply. JPMorgan Chase Bank N.A. Member FDIC. Copyright 2026. JPMorgan Chase and Company. We buy insurance for peace of mind, but every year millions of claims are denied. Not because people did anything wrong, but because their policies quietly excluded what happened.

48:43Insurers know every detail. Policyholders rarely do. That's why My Policy Advocate exists. For just 27 cents a day, their platform reads your policies and explains where you are vulnerable. They don't sell insurance. They deliver transparency. Before you trust your policy to protect you, let My Policy Advocate tell you what it really says. Go to MyPolicyAdvocate.com. It's time now for Talking Tech and First Up. SoftBank posted a jump in profit, fueled by valuation gains on its open AI investment. Founder Masayoshi-san has spent the last year pivoting the company's focus from venture startups to silicon and data centers.

49:21Plus, following a visit from Scott Besant, Japan's three megabanks are set to gain access to Anthropik's powerful Mythos model. That's according to the person familiar with the matter. Now the move comes despite a widespread alarm over Mythos and speculation about its potential cybersecurity risks. And Nebius, well, it's emerging as a powerhouse in the AI data center Gold Rush, reporting a 684 % jump in first quarter sales on increased demand for its own data centers. The company competes with a range of neocloud startups like CoreWeave that rent out computing resources to AI developers. Ed. OK, let's get back to what everyone's talking about today, and that's President Trump's meeting with Xi Jinping.

49:57And what to expect Bloomberg senior tech editor Mike Shepard joins us from DC. go to our senior tech editor because there is a big delegation of tech CEOs with the president. Jensen Wang is with him. And those are the issues on the table. Those are, and Ed, you know, the addition at the last minute and a really dramatic move of Jensen Wang to the trip certainly thrust artificial intelligence to the center of the discussions. It's unclear what sort of progress we will actually see in the areas that are most dear to NVIDIA. and that would be gaining more access to the Chinese market. They have one U.S.

50:33permission to sell those H200AI chips to customers in China, but Chinese authorities have been reluctant to allow their own producers to buy those chips en masse. And the reason is they want to promote and protect their own domestic chip-making industry, led by Huawei, led by CameraCon and SMIC. And yet there is the tension on the other side. They want their own artificial intelligence companies, the model developers, also to gain an edge. And they have been clamoring for that. And today we did see shares of Minimax, Knowledge Atlas, and even today U.S.-traded shares of Alibaba and Baidu all climb on the prospect that there could be more compute going to China.

51:15Talk to us about the names that were already solidified as going. Because Qualcomm's going, Micron's going. companies with exposure to China and they want to increase, where would they be fitting in to the ultimate demand equation here? Well, the broader demand equation, of course, for Micron, they have their own separate issues with China where they are almost company non grata at a certain level. Their role in the memory market is really key as well. And it's something that for chip makers and developers worldwide, they want to have a piece of being able to contribute to the creation of AI processors, not only designed by NVIDIA and by AMD, but by other companies as well.

51:57So they could be looking to push into there. And same with Qualcomm. Qualcomm, of course, has a lot of business when it comes to chips for mobile phones, and that could be a way in there. More broadly, when we look at this trip and its agenda, though, Carol, it's interesting that we see the White House Science and Technology Policy Advisor, Michael Kratzio, is there. And this could signal that AI and discussions around the technology will be really front and center. We could see the U.S. raise concerns about the practice of distillation that we have seen, where AI models are unfairly extracted, and also a working group created to discuss AI.

52:36Mike Shepard, across all the latest coming between those key talks in Beijing at the moment, we appreciate you rounding it up. But that does it for this edition of Bloomberg Tech, right here from San Francisco. We've got to get back to that breaking news that you helped break, Ed, earlier this hour. Talk us through why Arm was potentially looking to buy Cerebrus. Yeah, Arm and SoftBank tried to buy Cerebrus. Cerebrus said no, they will go public tomorrow. But Cerebrus makes supercomputers at scale for inference. And that's where the AI story is right now. That, of course, all according to Bloomberg sources.

53:06Recap that story and many others on the podcast. You know where to find it. Apple, Spotify, iHeart, and all of the Bloomberg platforms. This is Bloomberg Tech. When you're running a business, the best days are the ones where priorities stay on track. For midsize and large companies, risk can affect multiple parts of the organization at once, from property and liability to cyber and regulatory challenges. At that level, managing risk becomes an ongoing discipline. At the Hartford, the focus is on helping businesses manage risk before it turns into something more disruptive. And when losses do happen, that work is paired with insurance coverage shaped by years of underwriting, risk engineering, and claims experience.

53:47Learn more at thehartford.com slash risk mitigation. Policies provided by Hartford Fire Insurance Company and its property and casualty affiliates, Hartford, Connecticut. A business gift should do more than check a box. It should reflect your brand and show someone they're appreciated, recognized, and truly seen. 4imprint offers thousands of high-quality, customizable products like premium apparel, drinkware, tech, and more, making it easy to create a gift that feels meaningful and on-brand. And with 4imprint's expert support and their 360-degree guarantee, you can be 4imprint certain your order will arrive exactly as intended.

54:23Explore gifting with confidence at 4imprint.com. 4imprint. 4certain. Sonesta Travel Pass makes traveling more rewarding, designed to help you get more out of every stay. Sign up at sonesta.com to enjoy instant savings, bonus points and valuable perks like early check-in, late checkout, room upgrades, and free stays over time. With Senesta Travel Pass, every stay brings you closer to your next reward. Choose from more than 1 ,100 hotels across 13 distinctive brands and unlock the best available rates when you book direct with Senesta Travel Pass. Here today, roam tomorrow. Join now at senesta.com.

55:02Terms and conditions apply.